5-MeO-T-NB3OMe, or 5MT-NB3OMe, also known as N-(3-methoxybenzyl)-5-methoxytryptamine, is a serotonin receptor modulator and psychedelic drug of the tryptamine, 5-methoxytryptamine, and N-benzyltryptamine families related to the 25-NB (NBOMe) psychedelics. It is a positional isomer of 5-MeO-T-NBOMe (5-MeO-T-NB2OMe).
The drug shows affinity for many serotonin receptors and acts as an agonist of the serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors. It had similar affinity and activational potency at the human serotonin 5-HT<sub>2A</sub> receptor as 5-MeO-T-NBOMe. In addition, the drug had around 10-fold lower affinity for the human serotonin 5-HT<sub>2A</sub> receptor as 25I-NBOMe (25I-NB2OMe) but showed similar activational potency at this receptor as 25I-NBOMe. 5-MeO-T-NB3OMe produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It had similar potency in this test as 5-MeO-T-NBOMe and 25I-NB3OMe, but showed dramatically or 42- to 45-fold lower potency than 25I-NBOMe.
The chemical synthesis of 5-MeO-T-NB3OMe has been described. Various analogues of 5-MeO-T-NB3OMe besides 5-MeO-T-NBOMe have also been described.
5-MeO-T-NB3OMe was first described in the scientific literature by David E. Nichols and colleagues in 2015. It is not a controlled substance in Canada as of 2025. It is also not an explicitly controlled substance in the United States, but it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.